Adaptive Signature Design- review of the biomarker guided adaptive phase –III controlled design

Volume: 15, Pages: 100378 - 100378
Published: Sep 1, 2019
Abstract
Genomics having a profound impact on oncology drug development necessitates the use of genomic signatures for therapeutic strategy and emerging medicine proposals. Since its advent in the arena of clinical trials biomarker-related predictive methods for the identification and selection of patient subgroups, with optimal treatment response, are widely used. Genetic signatures which are accountable for the differential response to treatments are...
Paper Details
Title
Adaptive Signature Design- review of the biomarker guided adaptive phase –III controlled design
Published Date
Sep 1, 2019
Volume
15
Pages
100378 - 100378
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.